REGISTER NOW

SPEAKERS

Dr. David Rouquie: OASIS: a multi-stakeholder collaboration leveraging robust omics data to evaluate liver toxicity.
Dr. Jessica Ewald: Cell Painting as an emerging omics’ tool for toxicology and drug discovery.

David Rouquie leads the Toxicology Data Science team at the Bayer Crop Science toxicology facility in Sophia Antipolis, France. His passion for science and research that addresses societal needs has kept him deeply engaged in innovative, collaborative, and multidisciplinary projects. With a background in biochemistry and molecular biology, he is continually evolving into a hybrid profile at the intersection of biological and computational sciences. Recently, he joined the scientific committee of ECETOC as Bayer’s representative and serve a vice Chairman. In the context of the Broad Institute/HESI collaboration, he co-chairs the OASIS initiative alongside Dr. Anne Carpenter. This initiative aims to build confidence in the use of Cell Painting, transcriptomics, and proteomics for chemical safety assessments, using hepatotoxicity as a case study.

Jessica Ewald is a Banting postdoctoral fellow in the Carpenter-Singh lab at the Broad Institute, where she is developing statistical methods for using multi-omics data from in vitro screens for chemical toxicity detection. She holds a Bachelor of Science in Engineering Sciences and Applied Math from Harvard University, and a PhD in Bioinformatics from McGill University. For her thesis, she developed a suite of web-based tools for analyzing toxicogenomics data. She is passionate about maximizing the translational applications of her research, leading her to participate in multi-sector working groups on transcriptomic dose-response analysis and cross-species extrapolation, and to teach courses on her software at numerous conferences, workshops, and webinar series.

About DyNAMic Discussions: 

Regulatory Toxicology has reached a tipping point – animal tests are increasingly outmoded by New Approach Methodologies (NAMs) that offer the potential to improve human health and environmental protection.  So why is the transition out of animal testing and into a NAM-based approach to Chemical Safety Assessment predicted to take so long by so many commentators? And what can we collectively do to accelerate this transition?

This seminar series explores these questions by inviting speakers to share candid perspectives on how they’ve overcome barriers to apply NAMs in their fields and discuss how we can learn from these examples to increase NAM use together. Each presentation if approximately 30 minutes followed by an audience led Q&A. You can watch the webinar recording by following the link below.  And be sure to stay tuned for updates on the next DyNAMic Discussions webinar!

This series is moderated by Eryn Slankster-Schmierer, PhD, Physicians Committee for Responsible Medicine, Kristie Sullivan, MPH, Institute for In Vitro Sciences, and Gavin Maxwell, PhD, Unilever.

Learn more at: https://pcrm.org/Dynamic